Arsenal Capital Partners Buys Certara | GenomeWeb

NEW YORK (GenomeWeb News) – Private equity firm Arsenal Capital Partners today announced it has bought Certara, a provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.

Arsenal bought Certara from Vector Capital, which backed Jim Hopkins in forming Certara in 2007. Hopkins is now Certara's CEO.

The financial details of the acquisition were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.